
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Declared Initiation Of Eculizumab (Soliris®) Trial For Delayed Graft Function Prevention After Kidney Transplantation
Boston, MA 08/25/2014 (wallstreetpr) – Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that it will be starting clinical trial of eculizumab (Soliris®) in order to evaluate












